(Q43995286)

28 November 2017

Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats (English)

1 reference

28 November 2017

1 reference

0 references

1 reference

Pepita Giménez-Bonafé

5

1 reference

28 November 2017

Inés Rama

9

0 references

author name string

Núria Lloberas

1

1 reference

28 November 2017

Joan Torras

2

1 reference

28 November 2017

Gabriela Alperovich

3

1 reference

28 November 2017

Josep M Cruzado

4

1 reference

28 November 2017

Immaculada Herrero-Fresneda

6

1 reference

28 November 2017

Marcel la Franquesa

7

1 reference

28 November 2017

Marcel la Franquesa

8

1 reference

28 November 2017

Josep M Grinyó

10

1 reference

28 November 2017

language of work or name

English

0 references

publication date

9 May 2008

1 reference

Nephrology Dialysis Transplantation

28 November 2017

1 reference

28 November 2017

23

1 reference

28 November 2017

10

1 reference

28 November 2017

3111-3119

1 reference

The natural history of chronic allograft nephropathy

28 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Mycophenolate mofetil and sirolimus combination in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Importance of P-glycoprotein at blood-tissue barriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Do alloreactivity and prolonged cold ischemia cause different elementary lesions in chronic allograft nephropathy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Direct electrotransfer of hHGF gene into kidney ameliorates ischemic acute renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Kidney function and morphology after short-term combination therapy with cyclosporine A, tacrolimus and sirolimus in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Optimizing the immunosuppressive regimen in heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Cyclosporine and rapamycin act in a synergistic and dose-dependent manner in a model of immunosuppressant-induced kidney damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Expression and secretion of type beta transforming growth factor by activated human macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Phagocytosis of senescent neutrophils by human monocyte-derived macrophages and rabbit inflammatory macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Therapeutic role of TGF-beta-neutralizing antibody in mouse cyclosporin A nephropathy: morphologic improvement associated with functional preservation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Transforming growth factor beta in tissue fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

The role of vascular endothelial growth factor (VEGF) in renal pathophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FNDT%2FGFN223

21 January 2018

Identifiers

DOI

10.1093/NDT/GFN223

1 reference

28 November 2017

1 reference